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Abstract
Background: Expansion of designated cycling networks increases cycling for transport that, in turn, increases physical
activity, contributing to improvement in public health. This paper aims to determine whether cycle-network construction in
a large city is cost-effective when compared to the status-quo. We developed a cycle-network investment model (CIM) for
Oslo and explored its impact on overall health and wellbeing resulting from the increased physical activity.
Methods: First, we applied a regression technique on cycling data from 123 major European cities to model the effect of
additional cycle-networks on the share of cyclists. Second, we used a Markov model to capture health benefits from
increased cycling for people starting to ride cycle at the age of 30 over the next 25 years. All health gains were measured in
quality-adjusted life years (QALYs). Costs were estimated in US dollars. Other data to populate the model were derived from
a comprehensive literature search of epidemiological and economic evaluation studies. Uncertainty was assessed using
deterministic and probabilistic sensitivity analyses.
Results: Our regression analysis reveals that a 100 km new cycle network construction in Oslo city would increase cycling
share by 3%. Under the base-case assumptions, where the benefits of the cycle-network investment relating to increased
physical activity are sustained over 25 years, the predicted average increases in costs and QALYs per person are $416 and
0.019, respectively. Thus, the incremental costs are $22,350 per QALY gained. This is considered highly cost-effective in a
Norwegian setting.
Conclusions: The results support the use of CIM as part of a public health program to improve physical activity and
consequently avert morbidity and mortality. CIM is affordable and has a long-term effect on physical activity that in turn has
a positive impact on health improvement.
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Background
Studies suggest that cycle-network investments can in-
crease cycling [1–3] and thereby improve health at the
population level [4, 5]. The national and local govern-
mental authorities in Norway have aimed to support the
growth of cycling as a means of transportation with the
aim to improve health through increased physical activ-
ity. Although building new cycling infrastructure is ex-
pensive compared to “soft measures” such as marketing
campaigns for cycling promotion [6], improved cycling
infrastructure makes cycling safer and more attractive.
The health sector services are increasingly focusing on
providing more healthy years for all in Norway [7]. Thus,
there is a need to prevent diseases and diminish the ad-
verse impact of long-term medical conditions, and it was
shown that physical activity plays a vital role in this
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endeavor [2, 8]. Physical inactivity increases the risk of
lifestyle diseases and premature death. Specifically, phys-
ical inactivity is one of the leading modifiable risk factors
of global mortality, with an estimated 20–30% increased
annual risk of death compared to those who are physic-
ally active [9]. Further, physical inactivity was found to
be independently responsible for several chronic diseases
worldwide, including 6% of coronary heart disease
(CHD), 7% of type 2 diabetes (T2D), 10% of breast can-
cer, and 10% of colon cancer cases [10]. Thus, promot-
ing physical activity through cycling would have a wide
range of potential health benefits in Norway, where the
current cycling rate accounts for only 4% of total trans-
portation journeys [11].
To our knowledge, there have been no studies on
cost-effectiveness of cycle-networks construction in
Norway. One cost-benefit analysis has been conducted
on walking and cycling network investment initiatives in
three Norwegian cities (Hokkusund, Hamar, and Trond-
heim), which utilizes statistical value-of-life methods to
quantify the benefits of reduced mortality [12]. However,
the health-benefit criterion for health economic evalu-
ation is primarily concerned with health benefits mea-
sured in terms of quality-adjusted life-years (QALYs)
gained, and can thus be applied to any type of interven-
tion [7]. Cost-effectiveness studies of physical activity
that simultaneously model the direct and indirect health
benefits are sparse, and none is for Norway. In this
study, we assess the cost-effectiveness of planned cycle-
route investments in Oslo.
Methods
Change in cycling rates: regression analysis
We first address the effect of cycle network expansion
on cycling rates. We estimated the change in the mode
share of cycling resulting from cycling-network con-
struction using a nonparametric regression method,
which makes no assumptions about the functional form
of the relationship between the outcome and the covari-
ates. There is a lack of information on the association
between the increase in cycle ridership and the construc-
tion of cycle roads constructed every year in Norway.
Thus, data on cycling mode share and cycling network
length were obtained for 123 major European cities with
a population size of at least 100,000 from 11 European
countries: Austria, Belgium, Denmark, France, Germany,
Italy, the Netherlands, Spain, Sweden, Switzerland, and
the United Kingdom [13] (Additional file 1). Data on
cycling network lengths were retrieved from OpenStreet-
Map, and data on mode share and population size were
obtained through the European Platform on Mobility
Management Modal Split Tool [13–15]. The nonpara-
metric regression was extracted using the modal share of
cycling (in %) and cycle–networks length (in km per
100,000 population) as the independent and dependent
variables, respectively. Using the fitted equation, we pre-
dicted the percentage of expansion in cycle ridership for
every additional km of cycle length construction.
Model structure: decision analytic model
We developed a Markov state-transition model that exam-
ines the cost-effectiveness of investing in cycle-network con-
struction in Oslo. We refer to the model as the Cycle-
network Investment Model (CIM), which was developed
using the TreeAge Software (©TreeAge Pro 2020 (v2.1),
Williamstown, MA, USA). Markov modeling is commonly
used for the evaluation of long-term impact and cost-
effectiveness of interventions. It is based on a number of mu-
tually exclusive states into which the individual may or may
not move at defined points in the future, such as being
“physically active” or “physically inactive”. The model is re-
evaluated at different points of time (cycles), and after each
cycle, an individual may remain in the previous state or move
to a different one depending on transition probabilities. Costs
and outcomes (e.g. health) depend on the states and are cal-
culated and cumulated after each cycle. Markov models are
particularly well-suited to evaluate population-based health
promotion efforts where costs and outcomes appear over an
extended period of time [16].
Health outcomes and costs associated with the con-
struction of new cycle networks were compared to the
status quo (no intervention). Through CIM, we modeled
the incidence of four disease events related to physical
activity with and without additional cycling: CHD,
stroke, T2D, and cancer. We assumed that only a por-
tion of the cohort chooses cycling as their main means
of transportation, and that all cyclists were considered
physically active. We allowed for the possibility that
some of the non-cyclists could be active elsewhere and
achieve similar disease-risk profiles as the cyclists. The
insufficiently active (hereafter inactive) group consisted
of the portion of the population attaining less than 150
min of moderate-intensity physical activity per week
[17]. The proportion of non-cyclists achieving the rec-
ommended physical activity level (28.6%) was obtained
from the literature [18]. After cycle-network construc-
tion, individuals would settle into either “cyclists” or
“non-cyclists”, the latter being further subdivided into
the two states: “active” and “inactive”. The Markov
model structure with possible transitions is illustrated in
Fig. 1.
The risk of the four specified diseases declined over
time for the “active” group. The starting age of the co-
hort was assumed at 30 years because of the low risk of
non-communicable diseases due to physical inactivity
before age 30 and the paucity of data on younger age
groups. The time horizon of the CIM was assumed to be
25 years on the basis that active travel infrastructure
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might need rebuilding beyond such a horizon, and the
model was evaluated using cycle lengths of one year. Fu-
ture costs and health benefits were discounted at 4% per
year [19]. Willingness-to-pay thresholds of 600,000 NOK
($72,550) were used to determine the likelihood of cost-
effectiveness in all analyses, which is within the range
commonly used in Norway [20, 21].
Initially, we assumed that everyone starts in the “Well”
state (i.e. no disease). We assumed that health states in-
cluded in the model were mutually exclusive, and mem-
bers do not move between disease states. During each
annual cycle, an individual has a risk of moving to one
of the disease states or to the “Dead” state. Individuals
with T2D and cancer are assumed to either stay in their
states or die in the subsequent cycles. For CHD and
stroke, we assumed that a given proportion of events
would be immediately fatal and people who survived one
of these events would have an increased subsequent risk
of death. Individuals in the non-fatal states can stay in
that state, or move to the “Dead” state. The “Dead” state
is absorbing, meaning that no further transitions are
possible.
Disease risk and mortality
We conservatively assumed that the intervention of
building new cycle-networks influences the incidence of
disease only in healthy participants at risk. Initially, age-
specific incidence rates of cancer, CHD, stroke, and T2D
for the general Norwegian population were obtained [22,
23]. These incidence rates were then adjusted by
population-attributable fractions [10, 24, 25] to obtain
the probabilities of developing these conditions among
the inactive individuals (Table 1). Finally, the
probabilities of developing the specific diseases among
active individuals were derived using relative-risk (RR)
estimates identified from the literature (Table 2).
In the absence of direct probabilities for CVD-related
and other mortality among individuals with CHD,
stroke, and T2D, RRs for these conditions [27, 29, 30]
were applied to adjust for age-specific mortality rates
(Table 2). Age-specific mortality rates for CVD and all-
cause mortality were retrieved from Norwegian life ta-
bles and cause of death registries [26, 34]. Mortality con-
stituted disease-specific mortality and mortality due to
other causes. Mortality due to other causes was given by
all-cause mortality less mortality from the four disease
conditions included in the model. Individuals with can-
cer were assigned an increased risk of mortality using
data from the Finnish population based registry study
[31]. Due to the lack of Norwegian-specific data, case fa-
tality rates for CHD and stroke were taken from the
international literature [27, 28]. Because we are mainly
interested in the primary prevention of disease events,
the mortality risk from these events (conditional on hav-
ing the disease), except for T2D, was assumed to be in-
dependent of physical activity. For T2D, we also
assumed that the risk of death declined over time at a
faster rate for the active group than for the inactive
group [35, 36].
Cycle-network construction and cycle trips
The Oslo municipality has an ambitious plan to create a
network of 530 km cycle infrastructure in two phases,
where 70% of the costs are covered by the municipality
and the rest by the state government. Phase I is a 100
km cycle-network to be built by 2025 (i.e., an increase
Fig. 1 Markov transition model. Note: Circles represent Markov health states, and arrows indicate the transitions among these health states. Death
is an absorbing state from which no future transitions are possible, and Well is a disease-free state from which the Markov process starts. CHD1
fatal coronary heart disease, CHD2 non-fatal coronary heart disease, Stroke1 fatal stroke, Stroke2 non-fatal stroke, T2D type 2 diabetes
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from 180 km in 2015 to 280 km in 2025). The goal is to
increase the share of cycling to 25% upon the comple-
tion of phase I, which is much higher than the base
value of 6% [37].
Costs
All costs in the CIM are expressed in 2017 US Dollars
($), and the annual average exchange rate is assumed to
be 8.27 NOK per $1. All costs were defined as annual
costs per person (Table 3). Cost estimations for the
treatment of CHD and stroke were made according to
methods described in the NorCaD model [19] and a
stroke study in the Norwegian settings [39]. The treat-
ment costs of T2D [40, 41] and cancer [42] were esti-
mated from the literature in a Norwegian context.
The cost of intervention per capita was determined by
dividing the total cycle-network investment costs in
2017 by the Oslo population size (666,759) in that year.
This was assumed as a prior cost and thus was included
in the intervention arm as a one-time cost. Following
the Norwegian Public Roads Administration [38], an
average construction cost of 25,000 NOK per meter of
cycling networks was used. Following price adjustment
and currency conversion, the construction cost was esti-
mated at $3 million per km. In addition to construction
costs, an annual maintenance cost of approximately 7%
of the total investment cost was considered [37, 46].
Outcome measures
QALYs are the primary outcome measure of the model
and were obtained by weighting the time spent in the
various health states by the utility values associated with
each state. In the present study, health state utility values
were measured by the EuroQol five-dimensional ques-
tionnaire (EQ-5D) and assigned to all disease states and
the healthy state (https://euroqol.org/).
In addition to the direct health effect of cycling, in-
creased physical activity is assumed to improve well-
being. Only one study was identified that had estimated
the relationship between the amount of physical activity
and the score on the utility scale [47]. The mentioned
study and an analysis performed by the National Insti-
tute for Health and Clinical Excellence on promoting
physical activity [48] estimated that every 30 min of
physical activity resulted in a QALY gain of 2.22 × 10− 4
due to improvements in wellbeing. We used this value
to transform physical activity levels for the active group
into QALYs, which amounted to a QALY gain of
over 0.05 per year due to improvements in well-
being (Table 3).
Sensitivity analyses
To assess the robustness of the model results and how
uncertainties around input values and assumptions
might potentially influence them, we carried out sce-
nario and sensitivity analyses. In the scenario analysis,
we varied the time horizon of the model from the base-
line of 25 years to 20 years and then to 30 years to assess
Table 1 Age-specific annual probabilities of experiencing the different health events
Age Incidence [22, 23] Mortality rate [26] Case fatality rate [27, 28]
T2D Cancer Stroke CHD CVD All-cause CHD Stroke
30–34 0.0016 0.0011 0.0003 0.0001 0.00002 0.00046 0.0877 0.2346
35–39 0.0018 0.0016 0.0005 0.0003 0.00005 0.00059 0.0877 0. 2346
40–44 0.0031 0.0022 0.0010 0.0006 0.0001 0.00082 0.0877 0. 2346
45–49 0.0050 0.0035 0.0017 0.0010 0.0002 0.00136 0.0877 0. 2346
50–54 0.0076 0.0058 0.0025 0.0018 0.0004 0.00231 0.0877 0. 2346
55–59 0.0098 0.0087 0.0033 0.0029 0.0007 0.00384 0.1155 0.2328
60–64 0.0106 0.0134 0.0044 0.0046 0.0011 0.00610 0.1155 0.2328
65–69 0.0105 0.0190 0.0056 0.0069 0.0020 0.01052 0.2107 0.2347
70+ 0.0121 0.0252 0.0070 0.0102 0.0036 0.01742 0.2107 0.2347
Table 2 Relative risk of incidence and mortality for the disease
states
Disease Base value Lower Upper Distribution Source
RR of mortalitya
CHD 3.89 3.81 3.97 Lognormal [29]
Stroke 3.89 3.81 3.97 Lognormal [29]
T2D 2.61 2.34 2.88 Lognormal [30]
Cancer 4.20 4.00 4.30 lognormal [31]
Relative risk for disease (Active vs inactive)
Cancer 0.55 0.36 0.84 Lognormal [32]
CHD 0.80 0.75 0.86 Lognormal [33]
Stroke 0.82 0.77 0.87 Lognormal [33]
T2D 0.74 0.72 0.77 Lognormal [33]
aRelative risks (RRs) of CVD mortality except for cancer (which is RR of
all-cause mortality)
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the impact of the time horizon on the cost-effectiveness
of the intervention. Scenario analyses for 35 and 40 years
of time horizon have also been conducted to check the
influence of higher relative risk of the described diseases
at an older age. Further, given Oslo’s goal of a 25% mode
share for cycling by the year 2025 [37], this study con-
sidered four scenarios of cycle mode shares: 11.5, 15, 20,
and 25%. In addition, both one-way and probabilistic
sensitivity analyses were conducted to explore the effects
of key input parameters. In the probabilistic sensitivity
analyses (with 10,000 iterations), cost data, probabilities/
utilities, and relative-risk reductions were assumed to
follow gamma, beta, and log-normal distributions, re-
spectively. Gamma distributions are constrained on the
interval 0 to infinity, and hence appropriate to represent
uncertainty in cost parameters; beta distributions are
constrained on the interval 0 to 1 and suitable to model
uncertainties in probabilities or utilities; and RRs are ra-
tios with confidence limits calculated on the log-scale,




The nonparametric regression results show that the aver-
age marginal effect of cycle path length is 0.14%; i.e., a one
km increase in length of cycle paths leads to a 0.14% in-
crease in cycle modal share (Fig. 2). Based on this model,
the share of cycling would increase by 3% if Oslo’s cycle-
network length increased from 180 km to 280 km as per
Phase I of the cycle-network expansion plan in Oslo. After
adjusting by the base-line value of cycling, the chance of
cycling (modal share) after the cycle-network investment
becomes 9%. Alternatively, using the fitted model, we pre-
dicted that the probability of cycling would increase by
11.5% if a total of 280 cycle-network kms were con-
structed in 2025. The conservative value of 9% cycling
share is used in the base-case analysis. Other policies may
increase the share further, but are not considered here.
Cost-effectiveness analysis: base case analysis
The total costs, total QALYs, and incremental cost-
effectiveness ratio for the CIM are presented in Table 4.
Cycle-network construction as part of promoting phys-
ical activity produced an additional cost of $416 per per-
son and yielded 0.019 QALYs per person over the life
horizon of the intervention compared with the status
quo. The incremental cost per QALY gained (or ICER)
is $22,350 and thus can be considered highly cost-
effective at a threshold of $72,550 per QALY.
Scenario and sensitivity analyses
The scenario analyses (Table 4) revealed that the per-
centage share of cycling (following cycle-network invest-
ment) is a crucial parameter. If Oslo achieves its
ambitious plan of 25% modal share for cycling through
other forms of physical activity promotion, CIM alone
would be cost-effective at $1548 per QALY (excluding
Table 3 Cost and utility parameters
Description of Costs and utilities Cost ($) and utility values SD Distribution for sensitivity analysis Source
Costs
Investment cost, total/per capita 3,022,975/4.5 1.690 Gamma [38]
Maintenance cost, total/per capita 44,438/0.066 0.020 Gamma [12]
Cost of CHD 1st event 22,133 8300 Gamma [19]
Cost of post-CHD 1st event 21,597 8099 Gamma [19]
Cost of stroke 1st event 25,421 9533 Gamma [19]
Cost of post stroke 1st event 11,962 4486 Gamma [39]
Cost of T2D 5247 1968 Gamma [40, 41]
Cost of cancer 13,810 5179 Gamma [42]
Utilities
Healthy 1.00 Assumed
Cancer 0.74 0.015 Beta [43]
CHD1 0.47 0.016 Beta [28, 44]
CHD1+ 0.56 0.016 Beta [44]
Stroke1 0.50 0.036 Beta [44]
Stroke1+ 0.50 0.036 Beta [44]
T2D 0.81 0.190 Beta [45]
Wellbeing gain when active 0.05 0.013 Beta [28]
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other costs of achieving the planned share of 25% modal
share). Further, reducing the life of the project from 25 to
20 years had a considerable effect: the incremental cost
per QALY rose to $27,967. In contrast, increasing the life
of the project by 10 years (on top of the base-case time
horizon of 25 years) reduced the incremental cost per
QALY gained to two-thirds of the base-case value. This
substantial reduction in ICER is because the CIM’s incre-
mental benefits (or QALY gains) continue to accumulate
over an extended duration; at the same time, its incremen-
tal costs during the subsequent periods decline due to a
reduction in the risk of disease events (Table 4).
Fig. 2 Nonparametric regression between cycle path length (in km per 100,000 population) and cycling mode share
Table 4 Cost-effectiveness results comparing CIM with status quo
CIM Status quo CIM Incremental ICER
Cost QALY Cost QALY ΔCost($) ΔQALY ($/QALY)
Base case 6875 15.240 7291 15.259 416 0.019 22,350
Change cycle share
Predicted cycle share (11.5%) 6875 15.240 7220 15.273 345 0.033 10,292
Scenario 2 (15%) 6875 15.240 7188 15.297 313 0.057 5533
Scenario 3 (20%) 6875 15.240 7119 15.328 244 0.088 2766
Scenario 4 (25%) 6875 15.240 7060 15.359 185 0.119 1548
Time horizon
Scenario 5 (20 years) 4155 13.198 4589 13.213 434 0.015 27,967
Scenario 6 (30 years) 10,366 16.864 10,760 16.885 394 0.021 18,536
Scenario 7 (35 years) 14,420 18.139 14,782 18.163 362 0.024 15,366
Scenario 8 (40 years) 18,788 19.121 19,110 19.147 323 0.026 12,368
QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, CIM cycle-network investment model
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In the one-way sensitivity analysis, the most important
variable is the share of cycling, followed by well-being
from physical activity (Fig. 3). The lower the cycling
share and the wellbeing gain, the higher the ICER. How-
ever, plausible changes to the assumed effectiveness of
CIM led to ICER estimates that remained well below the
threshold of $72,550 per QALY. The analysis is generally
robust to variations in other key input parameters.
Figure 4 presents a cost-effectiveness acceptability curve
and a cost-effectiveness plane for each of the 10,000 simula-
tions. In general, the cost-effectiveness of cycle-network con-
struction compared to the status quo depends on the
decision-makers’ maximum willingness to pay per additional
QALY. The probability that the CIM would be cost-effective
at different thresholds of willingness to pay is depicted in
Fig. 4a (results produced based on 10,000 Monte Carlo simu-
lations). For example, the ICER for CIM compared with the
status quo was considered cost effective at $30,000 per
QALY, a threshold well below the commonly used value in
Norwegian settings (shown by a $72,550 per QALY threshold
line in Fig. 4b).
Discussion
This study assessed the cost-effectiveness of new cycle-
network investment using a Markov state-transition mod-
eling approach. The cycle-network investment compared
to the status quo is cost-effective as it is well below the
suggested threshold of $72,550 per QALY, at which there
is a 76% chance that the CIM will be cost-effective. Setting
other benefits aside, health and wellbeing benefits of
physical activity justify the investment in cycle infrastruc-
ture. This is more cost-effective than other health inter-
ventions provided in Norway such as acute ischemic
stroke treatment with intravenous thrombolysis through
‘mobile stroke unit’, which costs nearly two times more
(over $40,000 per QALY gained) [49].
Similar results have been found in previous studies on
the cost-effectiveness of cycling infrastructure to im-
prove physical activity, despite the difference in the
methodological approaches used. Gu, et al. [50] found
that investments in cycle lanes are more cost-effective
than the majority of preventive approaches used now-
adays. Other studies have also reported positive benefit-
cost ratios [1, 12, 51]. Recently, there has been a growing
need for health economic evaluations of such programs
because they assist decision-makers in establishing prior-
ities within cost-constrained health care budgets.
The base-case results were generally robust to prob-
abilistic and deterministic sensitivity analyses. The ICERs
modestly decline with an increase in the starting age of
the cohort, indicating that the payoffs would be higher if
the intervention is targeting older individuals. This
makes sense because aging is the main risk factor for the
development of multiple non-communicable diseases,
including cardiovascular diseases, cancer and diabetes.
This study is timely because it is relevant to the on-
going public and political debate about public health in-
terventions in Norway, and addresses the lack of
economic evidence on public health interventions. An-
other strength is the quantitative analysis of wider health
Fig. 3 An influence analysis (Tornado diagram). CHD coronary heart disease, T2D type-2 diabetes, ICER incremental cost-effectiveness ratio. Each bar
represents the range of outcomes produced when each input parameters is set to low (blue bar) and high values (red bar), with the other variables
being held constant. The solid vertical line represents the value of the outcome when the baseline values are used for all input parameters. The upper
bars represent input parameters that contribute most to the variability of the outcome
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aspects (including wellbeing) associated with the cycling
infrastructure. The use of a Markov model is also a
strength because it represents processes that evolve over
time, which is particularly suited for modelling the pro-
gression of chronic disease and interventions (e.g., cyc-
ling) that aim to reduce the risk or severity of diseases.
However, the study has a number of limitations. Costs
and utility data were taken from secondary sources. To
minimize the effect of such limitations, data from
Norway were used as much as possible. In the absence
of such data, information from similar studies was care-
fully retrieved from similar countries and reported here
with transparency. Further, uncertainty in the cost and
utility estimates was incorporated and analyzed in the
model through deterministic and probabilistic sensitivity
analyses.
The model included only cycle-network investment
and health care costs, and the results might vary if other
costs and productivity changes are included. In addition,
we might have underestimated the benefits of the pro-
gram by considering that the intervention only modifies
disease incidence, while it may also reduce the risk of
mortality [52]. Uncertainty with regard to gain in QALY
due to improvement in wellbeing resulting from in-
creased share of cycling could be another limitation, and
we might have overestimated the benefits if there is no
Fig. 4 Cost-effectiveness acceptability curve and cost-effectiveness plane showing results for 10,000 Monte Carlo simulations
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or only trivial wellbeing gain. Furthermore, the assump-
tion that all cyclists are active might not always hold be-
cause an increase in cycling might not translate directly
into an equivalent increase in overall physical activity.
Had only 90% of cyclists been assumed to be active, the
incremental cost per QALY would have increased by
11%.
Other disease conditions that may be affected by phys-
ical activity were excluded from the analysis. Such as-
sumptions might lead to underestimation of the cost-
effectiveness of the CIM. The exclusion of adverse ef-
fects of cycling (e.g., injuries), and additional favorable
effects of cycling (e.g., reduced air pollution and conges-
tion as well as wear and tear of roadways) constitute an-
other limitation. However, injuries are generally low and
less likely to significantly affect the results at the popula-
tion level [27]. Further, it has been argued that the net
number of fatalities and crashes would not increase with
investments in cycling [51]. The issue of air pollution is
also dynamic in the sense that cyclists could potentially
be exposed to higher doses of pollution even though
cycling reduces overall pollution emissions. The base-
case analysis assumed cost-effectiveness of cycle-
networks investment for people starting to ride cycle at
the age of 30 over the next 25 years (i.e., from age 30 to
55 years). This simplifying assumption likely yields con-
servative estimates, because prevalence of the diseases
and preventable mortality increase among older age
groups. We considered time horizons up to 40 years in
scenario analyses, and found that cycle-network invest-
ment becomes more cost-effective with longer analytical
horizons.
In cost-benefit analysis terms, the health benefits
(only) measured in monetary terms (value of statistical
life estimates), which are often used in the transport sec-
tor, would clearly be substantially larger than the invest-
ment costs. Thus, our study can reasonably justify the
need for further investment in cycle-networks as a cru-
cial part of improvements in health and wellbeing as well
as having an efficient urban infrastructure.
Conclusions
The findings of this study show that investments in cycle-
network construction in Oslo would be cost-effective.
Cycling can be done as part of daily travel routines, and
thus has the potential to reduce the risk of a range of
health conditions, mainly cancer, heart disease, T2D, and
stroke – all of which are preventable causes of premature
death. It can also delay mortality if such diseases develop.
Our findings provide evidence that cycle-networks invest-
ment may help increase overall physical activity levels and
thereby produce substantial health benefits. Thus, policy-
makers should focus on placing cycling at the heart of a
healthy transport policy making cycling a convenient, safe,
and attractive everyday activity.
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